1-PP-W | Acquired Von Willebrand Syndrome: Mechanisms and response to treatment | Pu-Lin Luo | Received |
1-MP-T | Comprehensive Care Delivery for Bleeding/ Blood disorders through Telemedicine (TM) with a variety of providers at multiple delivery sites | Roshni Kulkarni | Received |
2-PP-T | Dont Let My Brain Bleed Decreasing IVH rates in the NICU. | Linda Wyman-Collins | Received |
2-LB | Pilot Phase of a World Bleeding Disorders Registry | Jamie OHara | Received |
2-PP-W | FVIII activity of OBIZUR can be measured in hemophilic plasma with standard FVIII one-stage clotting assays | Peter L. Turecek | Received |
3-PP-T | Joints bleeding management in a developing country. | DIALLO Yacouba | Received |
3-PP-W | TREATMENT OF ACUTE HEMARTHROSIS AT THE HEMOPHILIA PATIENTS | Aziza Makhmudova | Received |
4-PO-W | NovoSeven(R) in the treatment of acquired haemophilia A: Results from the prospective study (ACQUI-7) in France | Annie Borel-Derlon | Received |
4-PP-M | Activation of neutrophils by plasma derived FVIII concentrates | Martin Brodde | Received |
4-PP-T | Cost and time effectiveness of telemedicine to deliver collaborative Hemophilia Treatment Centers (HTC) services to remote patients | Witkop Michelle | Received |
5-PP-T | Patient organization assessment of care delivery in treatment centres | David Page | Received |
6-PP-M | Improved pharmacokinetics and bleeding efficacy of recombinant Factor IX Fc-XTEN in hemophilia-B mice | Arjan van der Flier | Received |
6-PO-W | Anti-FVIII IgG1 titers correlate with Bethesda levels in patients with acquired hemophilia | Elizabeth Donnachie | Received |
6-PP-T | Parental confidence when dosing children with long acting factor products in relation to sporting activity. A pilot study. | Melanie Wilkinson | Received |
7-PP-T | Practice Characteristics of Genetic Counselors Serving the North American Bleeding Disorders Community | Rebecca Malouin | Received |
8-PP-T | When health care professionals express themselves: results overview of the qualitative phase of Hero initiative | Harley Souter | Received |
9-PP-T | CENTRAL VENOUS CATHETERS IN CHILDREN WITH HEMOPHILIA: A SINGLE CENTRE LONG-TERM EXPERIENCE | Marta Milan | Received |
9-PO-W | Acquired haemophilia A in a Jehovahs Witness | Jacek Trelinski | Received |
9-PP-M | In silico models for genotype/phenotype correlations of F9 gene mutations causing severe Hemophilia B | Lennon Meléndez Aranda | Received |
10-PP-T | Towards a new, patient-centric, model of hemophilia management | Alessandro Gringeri | Received |
10-PO-W | Diagnosis of von Willebrand disease in population of Western Mexico | Ara Rebeca Jaloma-Cruz | Received |
11-PO-W | Hypofibrinogenemia as the first sign of autoimmune disease | Erica Okazaki | Received |
11-PP-M | DNA methylation of Factor VIII secreting endothelial cells and several other endothelial cells in comparision to blood | Muhammad Ahmer Jamil | Received |
11-PP-T | National Survey of the 340B Pharmacy Income Program: Quantitative Evaluation of the Services Provided by US Hemophilia Treatment Centers | Marisela Trujillo | Received |
12-PO-W | Management of acquired hemophilia: a single center experience. | Eva Ivanová | Received |
12-PP-M | Protein aggregates in plasma-derived factor IX (pdFIX) concentrates support platelet activation and microparticle formation in vitro. | Martin Brodde | Received |
13-PP-T | Step forward in health care for children with hemophilia in Republic of Macedonia | Zorica Trajkova | Received |
13-PP-M | Comparison of Different Prophylaxis Regimens for Moderate/severe Hemophilia A Children | Darintr Sosothikul | Received |
13-MP-W | Algorithmic evidence-based phenotype screening and collaborative approach to attacking symptoms of nonadherence in patients with bleeding disorders | Jay Bryant-Wimp, RPh | Received |
14-PP-T | Successful pregnancy and delivery in a woman with Severe Hemophilia A | Shadan Lalezari | Received |
14-PP-M | The effects of a long-acting factor IX product (N9-GP) on wound healing | Maureane Hoffman | Received |
14-MP-W | Effectiveness of the uPatient Platform in Hemophilia Prophylactic Treatment | Glňria Sagarra | Received |
15-PP-M | Variations of Factor XIII level during pregnancy | Gianluca Sottilotta | Received |
15-PP-T | Carrier Career Counseling: Development of e-learning educational tool for hemophilia carriers and women in hemophilia extraction to support acquiring readiness for change | Akiko Kakinuma | Received |
15-PP-W | Collecting clinical data through a care management assessment form during telephone patient encounters: A study among patients of the Gulf States Hemophilia and Thrombophilia Center (GSHTC) in Houston, Texas 2014-2015 | Stephanie Gustafson | Received |
16-PO-T | Pregnancy and delivery in a woman with von Willebrand Disease type 2 M: successfull treatment with Wilfactin | Dorina Cultrera | Received |
16-PP-W | Adherence to treatment in Korean hemophilia patients | Eun Jin CHOI | Received |
16-PP-M | Influence of Complement factor H on Factor XIIIA activation: a preliminary study | Sneha Gupta | Received |
17-PP-W | Changes in adherence after initiating treatment with prolonged half-life clotting factors for hemophilia | Adi Eldar-Lissai | Received |
18-PP-W | Adherence to prophylactic treatment in patients with haemophilia in Germany | Wolfgang Miesbach | Received |
18-MP-T | Learning about women with bleeding through data | Cheryl DAmbrosio | Received |
19-PP-T | Results of a national registry for hemophilia A and B: Situation of the disease in Colombia | Patricia Sanchez | Received |
20-PO-M | Severe Congenital factor V deficiency in the north region of Turkey | canan albayrak | Received |
20-PP-T | Developing centralized web-based National Patients Registry: Pakistan Experience | Masood Malik | Received |
20-PP-W | perceived barriers to hemophilia treatment-a survey among parents of persons with hemophilia | Anjalin Dsouza | Received |
21-PP-T | Public Health Surveillance of People Not Receiving Care at US Federally-funded Hemophilia Treatment Centers: Methods and Demographics of the CHOICE Project | Wendy Owens | Received |
21-PO-M | Comparison of FXIII activity and antigen measurement during pregnancy | Mario von Depka | Received |
21-PP-W | Assessment of adherence to warfarin anticoagulation using the ratio of vitamin K dependent factors | Sarisha Naidoo | Received |
22-PP-T | Establishing a regional haemophilia registry in southern Tunisian | olfa kassar | Received |
22-PO-M | guardian5: a prospective non-interventional study of the treatment of severe and moderately severe haemophilia A with turoctocog alfa | AXON Turoctocog | Received |
22-PP-W | Validation of a scale of adherence to treatment in patients with hemophilia | Rubén Cuesta-Barriuso | Received |
23-PP-W | Adherence and the relationship to frequency of infusions in pediatric patients with hemophilia A and B | Karen Strike | Received |
23-PP-T | Associated factors to bleeding episodes in children diagnosed with hemophilia in a comprehensive care program in developing country | YADIRA VALDERRAMA VARGAS | Received |
24-PO-W | Adherence to treatment in patients with immune tolerance induction and patients on primary prophylaxis | Luis Cinara | Received |
24-PO-M | Safety and efficacy of B-domain deleted 3rd generation recombinant factor VIII (GreenGene F) in Korean patients with haemophilia A: Data from a post-marketing surveillance study | Soon Ki Kim | Received |
25-PP-T | Measuring the quality of hemophilia care across different settings: a set of performance indicators derived from demographics data | Mark Brooker | Received |
25-PO-M | The extent of VWF:Ag rise during moderate physical activity modulates FVIII half-life in severe haemophilia A subjects | CLEMENCE MERLEN | Received |
25-PO-W | Identification of psychological factors that interfere in the adherence to the treatment of patients with Haemophilia. | salguero Mariana | Received |
26-PO-M | A Novel Mutation in Child with Severe Congenital Factor X Deficiency | davut albayrak | Received |
26-PO-T | Psychosocial Impact of Mild to Severe Hemophilia B on Affected Adults and Children: Methods and Demographics of the Bridging Hemophilia B Experiences Results and Opportunities into Solutions (B-HERO-S) Study | Jane Cowley | Received |
26-MP-W | A successful nine year journey by a China-Canada professional group to transfer current hemophilia assessment tools to advance pediatric hemophilia care in China | Audrey Abad | Received |
27-PO-M | Patients Classification with Hemophilia A by FVIII Cromogenic Assay | Mirta Arias | Received |
27-MP-W | Effectiveness of Training Programme on Identification of Cases with Bleeding Disorder among Community Health Workers (CHWs) | sulochana b | Received |
27-PO-T | Demographic chracterization of patients older than 35 years with hemophilia, retrospective evaluation in a developing country | Claudia Casas | Received |
28-PP-W | Together Improving Haemophilia Healthcare in Kenya | Kibet P. Shikuku | Received |
28-PO-M | Evolution of clotting factor consumption over the last fifteen years for ambulatory hemophilia patients in a French comprehensive care center | Florianne Bel | Received |
29-PP-T | Joint Outcomes in United States (US) Hemophilia Patients: A Report of the Community Counts Registry | Becky Dudley | Received |
29-MP-M | Next Generation DNA sequencing for haemostatic and platelet disorders | Anne Goodeve | Received |
29-PP-W | Capacity Building in India - Integrating women into the picture | Gurmeet Khanna | Received |
30-PP-W | Importance of School Visits in Management of Hemophilia in Kenya | Phyllis Bartilol | Received |
30-PP-T | Korea Hemophilia Foundation registry trends 1991-2014: patient registry, demographics, health services utilization | Soon Ki Kim | Received |
30-MP-M | Preliminary Results of a Phase 1/2 Trial of SPK-9001, a Hyperactive FIX Variant Delievered by a Novel Capsid, Demonstrate Safety and Efficacy at the Lowest Dose Cohort | ALVIN LUK | Received |
31-PP-M | Discrepancy of F8 and F9 gene variant classifications between clinical laboratories | Michelle Alabek | Received |
31-PO-T | Can the use of data derived from different data sources improve regulatory procedures in a rare disease like Hemophilia A? | Christine Keipert | Received |
32-PP-M | Biopotency and efficacy of a FVIII gene therapy construct in hemophilia A mice | Werner Hoellriegl | Received |
32-PO-T | Comparison of parameters collected from clinical trials (performed in the frame of Marketing Authorization) and registries in severe Hemophilia A patients - A methodological exercise | Carla Jonker | Received |
32-PP-W | Establishing a Registry and Improving Diagnostic Capabilities and Treatment Outcomes for Persons with Hemophilia in Jamaica | Audrey Abad | Received |
33-PP-M | Development of a lead candidate for Baxaltas AAV8-based FVIII gene therapy program BAX 888 | Hanspeter Rottensteiner | Received |
33-PP-W | POSITIVE DIARIES: Testimonials of people living with bleeding disorders in Pakistan | Masood malik | Received |
34-PP-W | Women Empowerment | Nabila Husseni | Received |
34-PP-M | Messenger RNA Analysis and Multiplex Ligation Probe Amplification for Hemophilia A Patients without Found Mutation or Suspected Exon(s) Deletion in Genomic DNA | Yeu-Chin Chen | Received |
35-PP-W | Legal aspects: amparo action and compassionate use | Daniel Adolfo Luna | Received |
35-PP-M | An unexpected finding: two different coagulation factor VIII gene mutations in brothers | Michael Steiner | Received |
35-PO-T | A cross-sectional study of females with congenital bleeding disorders enrolled in the ATHNdataset | Kristina Haley | Received |
36-PP-M | Exploring the causes of skewed X-chromosome inactivation: XIST genetic analysis of cases and controls | Claudia Pamela Radic | Received |
36-PO-T | Inherited bleeding disorders - experience of a not-for-profit organization in Pakistan | Shabneez Hussain | Received |
36-PP-W | Women As Leaders | Nabila Husseni | Received |
37-MP-T | Are you HIRT? (Hemophilia Injury Recognition Tool): perceptions of the mobile app on injury self-management from young men with mild hemophilia in Canada | JoAnn Nilson | Received |
37-PP-W | BE, A youth employment pilot program: A Canadian HERO initiative | Ann Marie Stain | Received |
38-PP-M | Genetic variant analysis in children and adults with hemophilia: experience from a large hemophilia center in the US | Jennifer Lemons | Received |
38-PP-T | The role of social media in hemophilia care in Kenya | CHRISTOPHER MWANIKI | Received |
38-PP-W | Women with bleeding and leadership - a wicked problem? | Cheryl DAmbrosio | Received |
39-PP-W | Final transition of youth to adult hemophilia treatment center-a single center transition care project. | Karolina Lieponis | Received |
39-PP-T | Link nurse teaching day to bring haemophilia to ward nurses | Wandai Maposa | Received |
40-PP-W | The development of a Youth Ambassador Programme | Luke Pembroke | Received |
40-PP-M | Polygenic score analysis to find genetic factors of inhibitor development in Korean severe hemophilia A patients using WES | Hee Jo Baek | Received |
41-PP-W | Empowering and developing future community leaders to advocate and create awareness in their countries and in the region of Central America, the Caribbean and Venezuela. | FENDI VALDEZ BISONO | Received |
41-PP-T | Responsiveness of people with bleeding disorders and their families to educational modules on psychosocial challenges | Jessica Morrison | Received |
42-PO-M | Complexities and resolution of gene variant interpretation in two hemophilia cases | Stefanie Dugan | Received |
42-PP-T | Development of a Canadian video-based educational tool for teaching parents of children with hemophilia about joint assessment | Lawren De Marchi | Received |
42-PP-W | Factoring In youth: an online approach | Hannah Opeskin | Received |
43-PO-M | Systematic molecular analysis in Hemophilia A patients in a cohort from Bogotá, Colombia | Luz Yunis | Received |
43-PP-T | Empowering families of hemophiliacs to face challenges | Jayashri kale | Received |
44-PO-M | Factor VIII Gene Mutation and Hemophilic Arthropathy in Hemophilia A Patients | Tsung-Ying Li | Received |
44-PP-T | Von Willebrand Disease (VWD) Patient Conference in response to the 2014 Strategic Summit on VWD | Jeanette Cesta | Received |
44-PP-W | Blood pressure trends in relation to clotting factor utilization in patients with severe hemophilia | Richard Barnes | Received |
45-PP-W | a prospective study on vascular diseases in patients with haemophilia 2 years evaluation | Paul van der Valk | Received |
45-PO-M | National prevalence of F8 gene intron 1 and 22 inversions and development of inhibitors to factor VIII in Mexican severe hemophilia A patients | Ana Rebeca Jaloma-Cruz | Received |
46-PP-W | The orthopaedic treatment of haemophilic arthropathy in patients with inhibitors: a 15-year experience at a single Institution | Christian Carulli | Received |
46-PP-T | Use of electronic audience response system (ARS) during Von Willebrand Disease (VWD) patient conference | Jeanette Cesta | Received |
47-MP-M | Expanding the knowledge base: a collaboration between Saskatoon and Vancouver bleeding disorder teams | Jennifer King | Received |
47-PP-T | Parents Empowering Parents (PEP) Project: Evaluating its impact in providing effective parenting tools to parents of children with bleeding disorder in East and North India | Richa Mohan | Received |
47-PP-W | Endothelial activation markers and constitutional hemorrhagic diseases: defining normal STA-Procoag-PPL values | Dominique Desprez | Received |
48-PP-M | Hemophilia care in National Institute of Hematology and Blood transfusion, Hanoi, Vietnam | Mai Nguyen Thi | Received |
48-PP-T | A US National Program for Orientation of New Staff through the Regional Core Centers | Karen Droze | Received |
48-PP-W | Evaluation of bone mineral density in patients with haemophilia in a Colombian population | Edgar David Gomez Lahitton | Received |
49-PP-T | Getting closer to our patient: playing, learning and humanizing treatment - an experience of a Brazilian Center | Erica Okazaki | Received |
49-PP-W | Thrombotic and Cardiovascular Events in People with Hemophilia. Experience of a Single Hemophilia Centre | Beatriz Delgado | Received |
49-PP-M | Impact of Twinning between HTCs: Incremental Gain with Longitudinal Experience | Jonathan Kuriakose | Received |
50-PP-M | Bleeding Disorder Patient Perspectives on Information and Services Needs in a Remote US Pacific Island | Tiffany Lin | Received |
50-PP-W | Cardiovascular risk assessment in haemophilia patients at University Hospital in Ostrava | Radomira Hrdlickova | Received |
50-PP-T | The Bott-Harrington Nursing Fellowship in Bleeding Disorders: Broad dissemination of a nursing education tool kit | Sarah Crymble | Received |
51-PP-T | Development of a group intervention in Canada to provide education about joint assessment to adolescents and parents of children with Hemophilia | Celina Woo | Received |
51-PP-M | The impact of the World Federation of Haemophilia humanitarian aid program in conducting Circumcision for Haemophilia patients in Kenya. | INJERE AFUDE | Received |
51-PO-W | Prevalence of adult-onset medical comorbidities in Korean hemophiliacs | Hugh Kim | Received |
52-PP-T | PSYCHOEDUCATION WITH UPDATED FLASHCARDS: LETS PLAY AND LEARN ABOUT INHIBITORS, TREATMENTS AND HAEMOPHILIA | frederica RMY CASSIS | Received |
53-PO-T | The educational program Hemonline News | Gianluca Sottilotta | Received |
53-PP-M | Twining program Vietnam Hemophilia Association Irish Hemophilia Society | Mai Nguyen Thi | Received |
53-PO-W | Coronary by-pass surgery in patients with haemophilia A: single centre experience | Isil Erdogan Ozunal | Received |
54-PO-T | Development of a UK Haemophilia Data Managers Programme of Education | Lynne Dewhurst | Received |
55-PO-W | Coronary Angioplasty for Treatment of Coronary Artery Disease in mild PWH | Shashikant Apte | Received |
55-PO-T | Communication Through Design | Iman Rasheed | Received |
55-PP-M | Up-to-date informative sessions: an opportunity of empowerment | Otilia Ragull | Received |
56-PP-M | Organisational strategy to support members through 7 Key Life Stages | Liz Carroll | Received |
56-PP-T | An assessment of annualized bleed rates and quality of life among severe haemophilia A and B individuals in Europe | Alexandra Khachatryan | Received |
57-PP-T | A cost-effectiveness analysis of PK-driven prophylaxis using myPKFiT vs. standard prophylaxis in Haemophilia A | Alessandro Gringeri | Received |
57-PP-M | Assessing the Programming Needs of Patients/Clients of the Hemophilia Center at Oregon Health & Science University (HC) and the Hemophilia Foundation of Oregon (HFO) | Mina Nguyen-Driver | Received |
57-PO-W | Challenges of Hemophilia care in a developing country | ARCHANA VIJAY | Received |
58-PP-T | The relationship between treatment strategy and work productivity in severe haemophilia | Jason Booth | Received |
58-PO-W | Non-virus related cancer in people with haemophilia | Basak Koc | Received |
59-PP-T | An introduction to The Cost of Haemophilia across Europe - a Socioeconomic Survey (CHESS) | Charlotte Camp | Received |
59-PP-M | Causes and consequences in hospitalizations of patients with hemophilia in a hemophilia treatment center in Korea. | Jung Woo Han | Received |
60-PP-T | The cost of severe haemophilia in five European countries: the CHESS study | Charlotte Camp | Received |
60-PP-W | Rate of central venous line infections in people with bleeding disorders and home care services | Crystal Blankenship | Received |
60-PP-M | The Catalan Association of Hemophilia celebrates 40 years | Otilia Ragull | Received |
61-PP-W | Twenty-three years of HIV infection in hemophilic patients | Maria Coutinho | Received |
61-PP-T | Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis | Abiola Oladapo | Received |
61-PP-M | Medical care provided by a private clinic with the highest number of hemophilia patients in the region | Masue Kajiwara | Received |
62-PP-W | Treatment of HCV Infected Young Hemophiliacs Expectations to Cure Hepatitis C | Katalin Koehler-Vajta | Received |
62-PP-M | Collaboration between National Member Organisation (NMO), French Hemophilia Society (AFH Comity Midi-Pyrénées) and Belgian Hemophilia Society (AHVH) during diving courses | Patrick Finders-Binje | Received |
62-PP-T | The relationship between bleeding frequency and EQ-5D in severe haemophilia | Booth Jason | Received |
63-PP-T | Home infusion model can reduce factor consumption | Kirstin Schmidt | Received |
63-PP-W | Treatment of chronic hepatitis C (CHC) in haemophiliacs with the new direct acting antiviral drugs (DAAs) | PANAGIOTA IOANNIDOU | Received |
63-PP-M | Expectations and Concerns towards the Up-Coming New Long-Acting Products - Results of a Survey among Haemophilia Patients in Switzerland | Sylvia von Mackensen | Received |
64-PP-M | Regional hemophilia project in Turkey | Basak Koc | Received |
64-PP-T | Impact of mild to severe hemophilia on education and work by US adult men and women and caregivers of children with hemophilia B: the bridging hemophilia B experiences results and opportunities into solutions (B-HERO-S) study | Jane Cowely | Received |
65-PO-W | managing infectious complications of hemophilia, the experience of Constantine Center, Algeria | SIHEM KEBAILI | Received |
65-PP-T | U. S. Hemophilia Physician Prescribing Practices: Then and Now | Brenda Riske | Received |
65-PP-M | Hemophilia : A single-centre experience of 12 years. | HANDE KIZILOCAK | Received |
66-PO-M | Be-Coag, the hemophilia card with a basic medical file on the net | Patrick Finders-Binje | Received |
66-PP-T | Real world dosing and therapy switching patterns on rFVIII-Fc in the United States | Booth Jason | Received |
66-MP-W | Inhibitor risks in Argentine patients with severe HA. F8 genotype, status concordance in sibling pairs and immune gene polymorphisms studies | Claudia Pamela Radic | Received |
67-MP-W | Risk factors associated with High-titre Inhibitors development in Previously Untreated Hemophilia A patients (PUPS-HA) born between 2000 and 2013: A single center experience | Arlette Ruiz de Saez | Received |
67-PP-T | Use of Adding T2 Mapping Sequence to a Routine MR Imaging Protocol to Evaluate of the Articular Cartilage Changes of the Knee and Ankle Joint with Hemophilia in Children | Ningning Zhang | Received |
67-PO-M | Support network for Barcelona family carers: a way of embracing efforts working together between entities | Patricia Cabre | Received |
68-PO-M | A new challenge: twinning between the Catalan Association of Hemophilia (ACH) and the Cuban Society of Hemophilia (SCH) | Ana Fernández | Received |
68-PP-T | A Comprehensive Online Communication and Education Strategy for Hemophilia Treatment Centers (HTC) | Jerome Teitel | Received |
68-PP-W | Preliminary in vitro results from the PredicTGA study: thrombin generation assay (TGA) as a test of haemostatic effectiveness of factor VIII concentrates in patients with Hemophilia A and inhibitors | Armando Tripodi | Received |
69-MP-M | Heat treated Bethesda assay in the monitoring of acquired haemophilia A | annette bowyer | Received |
69-PP-W | Impact of FVIII source in the Bethesda-Nijmegen inhibitor test result. Difference between FVIII/VWF complex concentrates and concentrates of isolated FVIII | Maria Isabel Bravo | Received |
70-PP-W | Combined FEIBA- FVIII therapy a potential treatment for patients with hemophilia and inhibitors- a thrombin generation based study | Tami Livnat | Received |
70-PO-T | Testicular haematoma. Diagnostic and monitoring by Magnetic Resonance (MR) | Horacio Caviglia | Received |
71-PO-T | Long-Term Health Outcomes Comparison between Prophylaxis and On-Demand aPCC Treatment in Patients with Severe Haemophilia A with Factor VIII Inhibitors in Spain | Juan Pablo Garcia | Received |
71-PP-M | Thrombin generation assay triggered with tissue factor or factor XIa in patients with severe haemophilia A | Hassan Naeem | Received |
72-MP-T | PROTECT VIII Kids trial results: BAY 94-9027 safety and efficacy in previously treated children with severe hemophilia A | Elena Santagostino | Received |
72-PP-M | Clinical application of rotational thromboelastometry (ROTEM) in the diagnostic work-out of thrombocytopenia | Adela Gwozdowska | Received |
72-PP-W | Primary prophylaxis and inhibitor development in patients with severe Hemophilia A and B | marilia renni | Received |
73-PP-W | Thrombin generation assay (TGA) for testing haemostatic response in patients with Hemophilia A and inhibitors on immune tolerance induction treatment (ITI): preliminary in vivo results from the PredicTGA study | Armando Tripodi | Received |
73-MP-T | Is there a difference in inhibitor incidence with recombinant products? A meta-analysis of 2000 previously untreated patients | Alessandro Gringeri | Received |
73-PP-M | A validated patient-specific numerical model of thrombin generation for the management of hemophilia | Pierre Chelle | Received |
74-MP-T | Individual baseline thrombin generation and bleeding rate during personalized prophylaxis with Nuwiq in previously treated patients with severe haemophilia A | Joris Versteden | Received |
74-PP-W | Analytical performance of the Nijmegen assays using different buffered reagents. | Yuen On Wan | Received |
75-MP-T | Transition to Fc-fusion recombinant factor IX using a pediatric PK based protocol: Real life individualized prophylaxis | Kimberly Jacobson | Received |
75-PP-W | Inhibitor incidence in a cohort of South African people with severe hemophilia A is not higher than for Caucasian patients. | Ziphozonke Mafika | Received |
75-PP-M | Thromboelastography may help to define haemostatic safety zones for the practice of sport in patients with severe haemophilia A | Ihosvany Fernandez | Received |
76-PP-M | Bleeding Score: normal values for healthy young adults | Karina Meijer | Received |
76-MP-T | Validation of the Colorado Adult Joint Assessment Scale in adult patients with severe hemophilia A | Sharon Funk | Received |
76-PP-W | REal life MAnagement of children with severe hemophilia A and INhibitors: first results of the REMAIN study. | Maria Elisa Mancuso | Received |
77-MP-T | Effect of Moderate Intensity Exercise on Hemostatic Capacity in Adults with Hemophilia A and B: Pilot Study | Michelle Sholzberg | Received |
78-PP-W | South Mimms Inhibitor Assay (SMIA): an affordable and improved method for measurement of FVIII inhibitors | Sanj RAUT | Received |
78-PP-T | Hematuria is a Frequent Finding on Routine Urinalysis in Pediatric Patients with Hemophilia | Kyle Davis | Received |
78-PP-M | Endogenous thrombin generation potential: an added value parameter to individualize prophylaxis treatment in pediatric hemophilic patients? | PHU QUOC LE | Received |
79-PP-M | Application of global coagulation assays in Hemophilia B patients to evaluate the hemostatic potential in baseline conditions and after FIX concentrate administration. | Cristina Santoro | Received |
79-PP-T | Reduction in Dosing Frequency and ABRs in Previously Treated Pediatric (12 years) Patients With Severe Hemophilia A During Prophylactic Treatment With Pegylated Recombinant Factor VIII Compared to Pre-Study Prophylactic Regimen | Jennifer Doralt | Received |
79-PP-W | Bleeding characteristics of patients with congenital hemophilia and inhibitors: data from a postmarketing study of recombinant activated factor VII (SMART-7) | Harley Souter | Received |
80-PP-T | Transition to Fc-fusion recombinant factor VIII using a pediatric PK based protocol: Real life individualized prophylaxis | Kimberly Jacobson | Received |
80-PP-M | Role of bleeding score and laboratory testing in women with menorrhagia to identify inherited bleeding disorders: the experience of a tertiary care hospital in South India | Annamma Kurien | Received |
81-PP-T | Use of Power Doppler Ultrasound in Haemophilia Could Predict Early Relapse of Intra Articular Bleeding after Haemarthrosis: A Prospective Cohort of 27 Haemarthrosis Monitored By Articular Ultrasound | Laurent Frenzel | Received |
81-PP-W | Low-titer inhibitors in children with severe hemophilia A: real-life data from the REMAIN study. | Maria Elisa Mancuso | Received |
82-PP-T | Dosing Regimens Before and Following Long-Term Treatment With Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Adults and Adolescents With Severe Hemophilia A | Barbara Konkle | Received |
82-PP-W | Development and evaluation of a novel FVIII domain-specific multiplex microsphere based immunoassay for characterization of anti-FVIII antibodies | Behnaz Pezeshkpoor | Received |
82-PO-M | Evaluation of the Sebia Hydragel von Willebrand factor (VWF) assay compared to an in-house agarose gel electrophoresis method for VWF multimer analysis | KAREN GOODFELLOW | Received |
83-PP-W | Prevalence of Inhibitors in Hemophilia - A single centre study. | PARISMRITA BORAH | Received |
83-PP-T | Post Hoc Analysis to Evaluate the Effect of Recombinant Factor IX Fc Fusion Protein (rFIXFc) Prophylaxis in Adults and Adolescents with Target Joints and Hemophilia B | Roshni Kulkarni | Received |
84-PP-W | Anti- factor VIII IgG4 and intracellular cytokines profile in T and B cells from hemophilia A patients with complete success, failure, or relapse after immune tolerance induction treatment: longitudinal evaluation with five years follow-up | Montalvao Silmara | Received |
84-PO-M | Enhancing appropriate utilization of coagulation tests | Michelle Sholzberg | Received |
84-PP-T | Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin (rIX-FP) in hemophilia B patients undergoing surgery | Carol Hills | Received |
85-PP-T | Carriers of Haemophilia B Leyden: Factor IX levels during life | Sophie Aapkes | Received |
85-PP-W | Prophylactic treatment and Rituximab subsequent immune tolerance induction therapy to improve inhibitor eradication on resistant ITI in severe hemophilia A patients with inhibitor | Shin-Nan Cheng | Received |
85-PO-M | Activated partial thromboplastin time (APTT) of persons with haemophilia A can serve as a surrogate marker of their factor VIII activity | Teruhisa Fujii | Received |
86-PP-T | Characteristics of pediatric previously treated patients with severe hemophilia A aged less than 12 years experiencing no bleeds during a 6-month prophylactic treatment regimen with pegylated recombinant factor VIII | Jennifer Doralt | Received |
86-PO-M | Postoperative TGA monitoring of haemostasis of haemophilia patients with inhibitor (Second report) | fujihiko MINAMOTO | Received |
86-PO-W | Final results of the Prospective Advate ITI Registry (PAIR) Immune Tolerance Induction (ITI) experience with Advate | Jimena Goldstine | Received |
87-PP-M | A method to solve the issue of emicizumabs interference with FVIII:C and FVIII inhibitor titer assays | Tetsuhiro Soeda | Received |
87-PO-W | Variable Success with Immune Suppressive Therapy in Rescuing Immune Tolerance Induction in Children with Severe Haemophilia A, FVIII inhibitors and unfavorable prognostic factors | Viacheslav Dmitriev | Received |
88-PO-W | Prophylaxis with FEIBA three days a week results in safe and effective hemostasis in children with Hemophilia A with inhibitors | Mark Belletrutti | Received |
88-PP-T | Immune tolerance induction in adult patients with severe haemophilia A and long lasting inhibitors | Anna Buczma | Received |
89-PP-T | Safety and efficacy of a pegylated full-length recombinant factor VIII with extended half-life in previously treated children with hemophilia A | Jennifer Doralt | Received |
89-PP-M | Interaction of BAX 826 (PSAylated rFVIII) with VWF and LRP1 An in vitro and in vivo assessment | Gerald Schrenk | Received |
90-PP-M | Increasing the in vivo half-life of factor VIIa by attachment of the natural polysaccharide heparosan | Jesper Haaning | Received |
90-PO-W | Status of inhibitor hemophilia patients in different age groups | Nadezhda Zozulya | Received |
90-PP-T | A Study of the seroprevalence of Adenovirus-Associated Virus Vectorserotype AAV5 neutralizing activity and antibodies in Patients with Haemophilia A | Sophia Stanford | Received |
91-PP-T | Effect of factor VIII concentration on the risk of spontaneous bleeding following treatment with rFVIII (turoctocog alfa) in patients with severe hemophilia A | Harley Souter | Received |
92-PP-T | Long-Term Safety and Efficacy of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Adults/Adolescents With Hemophilia B: Longitudinal Analysis of B-LONG and B-YOND | Johnny Mahlangu | Received |
92-PP-M | Anti-factor IXa/X bispecific antibody emicizumab (ACE910) does not interfere with antithrombin or TFPI activity | Mariko Noguchi-Sasaki | Received |
93-PP-M | Efficacy of BAX 826, a polysialylated full-length rFVIII, in mouse models of hemophilia A | Werner Hoellriegl | Received |
93-PO-W | Haemophilia A with inhibitor in children: Experience of a single center in the last 25 years | Zafer Salcioglu | Received |
94-PP-M | Structural and functional characterization of preclinical and clinical batches of BAX 826, a PSAylated full-length recombinant FVIII | Gerald Schrenk | Received |
95-PO-W | Immune Tolerance Induction in Hemophilia A a Single Center Experience | Maria Coutinho | Received |
95-PP-M | FVIIa-CTP, a novel long acting FVIIa, Comprehensive Pharmacokinetics and Pharmacodynamics and Bioavailability evaluation following Subcutaneous (SC) and Intravenous (IV) administration to hemophilic animal models. | Doron Calo | Received |
96-PP-M | In-vitro Evaluation of Factor VIIa-CTP, a Novel Long-Acting Coagulation Factor | Doron Calo | Received |
96-PP-T | Course of target joint bleeding with prophylaxis of a pegylated full-length recombinant factor VIII with extended half-life in patients with hemophilia A | Lisa Patrone | Received |
97-PP-T | Safety and efficacy of turoctocog alfa for prophylaxis and treatment of bleeding episodes in patients with severe hemophilia A: results from the guardian2 trial | Harley Souter | Received |
97-PO-W | Long-term course of inhibitors against factor VIII concentrates in hemophilia A patients | KIYOUNG YOO | Received |
98-PP-M | Factor VIIa-CTP , a novel FVIIa potentially supporting subcutaneous treatment - comprehensive assessment in Hemophilic animals models in preparation for first in human study. | Doron Calo | Received |
98-PO-W | Sequential combined bypassing therapy for refractory bleeding in two adolescent hemophiliacs with inhibitors | Zhre Kaya | Received |
98-PP-T | Dosing Regimens Before and Following Long-Term Treatment With Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Children With Severe Hemophilia A | Beatrice Nolan | Received |
99-PP-M | Clinical and laboratorial evaluation of recombinant FVIII Fc fusion protein treatment in hemophilia A patients: a real-life in a single center | marion echenagucia | Received |
99-PP-T | A case of unexpected moderate haemophilia A in a female neonate within a family with mild haemophilia A in affected males: what happened? | Marjolein Peters | Received |
99-MP-W | World-wide field study of FVIII activity assay variability of ADYNOVATE, the PEGlylated form of rFVIII ADVATE, in clinical hemostasis laboratories | Peter L. Turecek | Received |
100-PP-M | Video Games addiction as it relates to children with hemophilia in Japan | Kayoko Omura | Received |
100-PP-W | Assay Discrepancies for New Generation FIX Products | Elaine Gray | Received |
101-PP-M | The importance of immunizations in patients with hemophilia | Maria Sol Cruz | Received |
101-PP-W | A modified IS-PCR protocol for easy detection and interpretation of inversion 22 in severe haemophilia A | CLEMENCE MERLEN | Received |
101-PP-T | Plasma tissue factor pathway inhibitor (TFPI) levels in healthy subjects and patients with hemophilia A and B | Jian-Ming Gu | Received |
102-PP-T | Local and general tolerability of Advate reconstituted in 2-mL rather than 5-mL SWFI: a pediatric post-authorization safety surveillance study | Jimena Goldstine | Received |
102-PP-M | A Genetics Day to Facilitate Efficient Enrollment for a National Project | Nancy Hatcher | Received |
102-PP-W | Does participation in an External Quality Assessment Scheme impact routine laboratory practice? A review of participant data from CMCEQAS over the last 6 years. | Joy Mammen | Received |
103-PO-M | Participation in school events of childrens with haemophilia in the era of prophylaxis in Japan | Tomie FUJII | Received |
103-PP-W | Harmonisation of the dilution factor in the Factor VIII Inhibitor test improves the between-laboratories comparability | Piet Meijer | Received |
103-PP-T | First report of safety and efficacy of a glycoPEGylated FVIII (N8-GP) in previously treated pediatric patients with severe hemophilia Aresults from the international phase 3 pathfinder5 trial | harley souter | Received |
104-PP-W | Relationship between coagulometric tests, clinical symptoms and the PCR test on fVIII haemophilia carriers | Marcela Alejandra Mardones Montanares | Received |
105-PP-M | Developing a regional Dental Services Pathway for inherited bleeding disorders in North London, UK | Heather Williams | Received |
105-PP-T | Long-term Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Adults/Adolescents With Severe Hemophilia A: United States Subgroup Analysis of A-LONG and ASPIRE | Doris Quon | Received |
105-PP-W | Results from a multi-national survey of FVIII activity assay preferences | Peter L. Turecek | Received |
106-PP-T | An Integrated Analysis of Long Term Safety of an Extended Half-Life, Pegylated, Full-length Recombinant Factor VIII (BAX 855) in the Treatment of Hemophilia A in 234 Pediatric, Adolescent and Adult Patients | Jacqueline Dyck-Jones | Received |
106-PP-W | The application of thrombin generation assays is compromised by low levels of antithrombin III | Sabine Knappe | Received |
106-PO-M | Training sessions on dental care for patients with hemophilia and von Willebrand disease | Maria Sol Cruz | Received |
107-PP-T | Iliopsoas hemorrhage in congenital factor deficiencies | Zafer Salcioglu | Received |
107-PP-W | Selection of trigger conditions influences the effect of Factor VIII on thrombin generation in hemophilia A plasma | Sabine Knappe | Received |
107-PO-M | The Wand Single Tooth Anaesthesia System is a safe and effective method of anaesthetising lower molar teeth for restorative treatment in patients with congenital coagulopathy. | Tara Dunseith | Received |
108-PP-W | Identification and characterization of the vitamin K binding pocket in human VKORC1 | Katrin Czogalla | Received |
109-PO-M | Main Manual for dental management of patients with Hemophilia and von Willebrand in Argentina | Maria Sol Cruz | Received |
109-PP-W | Hemoglobin variability in anemic adults one and six hours after packed red blood cell (PRBC) transfusions. | Jose Mauricio Garcia Habeych | Received |
110-PP-W | Modified primary prophylaxis in previously untreated patients with severe hemophilia A in Iran | Mehran Karimi | Received |
110-PO-M | A review on dental practice. Experience from a hemophilia treatment center | Luis Cinara | Received |
111-PO-M | Benefits of a swollen surgical site modification during a programmed tooth extraction | Luis Cinara | Received |
111-PP-W | Pain assessment and management in hemophilia: a survey among Italian patients and specialist physicians | Gianna Franca Rivolta | Received |
111-PP-T | 2nd interim analysis results of the global ahead study in hemophilia A patients | Alessandro Gringeri | Received |
112-PP-W | Circumcision experience and management of complications in hemophiliac patients | Ilgen Sasmaz | Received |
112-PO-M | PREVENTION TREATMENT FOR PATIENTS WITH HEMOPHILIA Design of a Diagnose Survey Model | Miryam Parreira | Received |
113-PP-W | Estimation of annual bleeding management cost in severe haemophilia A patients, without inhibitors, treated with on-demand therapy with recombinant factor VIII in Spain. | Juan Pablo Garcia | Received |
113-PP-T | Interim results of a Phase IIIb safety and efficacy extension study of a recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in patients with hemophilia B | Carol Hills | Received |
113-MP-M | Total Ankle Replacement (TAR) in Haemophilic Arthropathy of the Ankle | sanghoon lee | Received |
114-PP-M | FRAX and the assessment of fracture probability in patients with severe and moderate Haemophilia A & B. | Alexandra Agapidou | Received |
114-PO-W | The Diagnosis and Treatment Status of Children Hemophilia in China | Min Zhou | Received |
115-PP-M | Relationship between the ultrasound evaluation and the clinical examination of joints in patients with hemophilia on primary prophylaxis | Luis Cinara | Received |
116-PO-W | Respond time in providing clotting factor to patient with hemophilia in Manado | Stefanus Gunawan | Received |
116-PP-T | Intracranial haemorrhages (2000-2015): 7 centre pediatric experience in Argentina | Monica Martinez | Received |
117-PP-T | Examination of Reduced Volume APCC (activated prothrombin complex concentrate-(FEIBA) for Accelerated Infusion in Adult Hemophilia A or B Patients with Inhibitors | Jennifer Doralt | Received |
117-PO-W | Clinical profiles of Malagasy hemophiliac patients with iliopsoas hematoma in the Surgical Intensive Care Unit CHU JRA Antananarivo Madagascar | Rakoto Alson Aimée Olivat | Received |
118-PO-T | Articular condition in children and adolescents with severe hemophilia A on prophylaxis: clinical assessment and ultrasound examination | Ihosvany Fernández-Bello | Received |
118-PP-M | High-resolution musculoskeletal ultrasound with power Doppler (MSKUS/PD) for hemophilic mouse joints provides a non-invasive model to study location-specific clustering of vascular changes associated with joint bleeding in hemophilia | Esther Cooke | Received |
118-PP-W | Preoperative overdosing in mild hemophilia A patients: an analysis of possible risk factors (DAVID studies) | Lisette Schtte | Received |
119-PP-M | Reduced Bone Mineral Density in Children and Adolescents with Hemophilia from East Turkey | Murat Sker | Received |
119-PO-T | Impact of training of primary care health professionals and patients with hereditary bleeding disorders on quality of treatment | Alessandra Loureiro Prezotti | Received |
119-PP-W | Prevalence of discrepancy between one-stage and chromogenic FVIII activity assays and the mutation profile in Polish mild/moderate haemophilia A patients | Beata Baran | Received |
120-MP-W | The development of a software for musculoskeletal evaluation database | Janaina Ricciardi | Received |
121-PP-W | Comparison of clinical characteristics and health care utilization among individuals with hemophilia A and B in the Hemophilia Utilization Group Studies (HUGS) cohorts | Mimi Lou | Received |
121-PP-M | HAEMOcare: an international epidemiological study of musculoskeletal disease burden in haemophilia patients in developing countries | Johnny Mahlangu | Received |
122-PO-T | Long-term safety and efficacy of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in previously treated patients with hemophilia B | Carol Hills | Received |
122-PP-W | An alternative model of comprehensive care for geographically challenged hemophilia treatment centers in the United States | Michelle Witkop | Received |
123-PO-T | Striving for a bleed free world an interim analysis from the AHEAD Global & German studies | Alessandro Gringeri | Received |
124-PO-T | The use of turoctocog alfa for the prevention and treatment of bleeds in patients with hemophilia A: efficacy data from European countries included in the guardian2 clinical trial | Harley Souter | Received |
124-PP-M | The spectrum of haemophilic pseudotumours:Management at a single centre in India | Sandeep Albert | Received |
124-PP-W | Hemophilia Joint Health Score v2.1 in US Adults With Hemophilia in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study | Jane Cowley | Received |
125-PO-T | The experience of surgery in hemophilia patients with inhibitors | Ilgen Sasmaz | Received |
125-PP-W | Joint outcomes in adults with hemophilia A on prophylaxis in Scandinavia: results from the KAPPA register. | Mehdi Osooli | Received |
125-PP-M | TREATMENT VACUUM-ASSISTED CLOSURE SYSTEM (VAC) IN A PATIENT WITH HEMOPHILIC PSEUDOTUMOR IN PELVISA CASE REPORT | Eugenio Quevedo Ramos | Received |
126-PP-M | Anterior osteophytes resection of the ankle joint to increase range of the ankle motion in haemophilic patients | Myung Chul Yoo | Received |
126-PO-T | Arteriovenous fistulas for clotting factor administration in adults with severe bleeding disorders | Jerome Teitel | Received |
127-PP-W | An assessment of anxiety levels in 100 haemophilia patients from Northern India using validated S.T.A.T. scale | Naresh Gupta, M.D. | Received |
128-PO-T | Monitoring for efficacy anc safety during switching to new hemophilic products | Hugh Kim | Received |
128-PP-W | Reseach on characteristics and causes of death in hemophilia patients managed in National Institute od Hematology and Blood transfusion | Mai Nguyen Thi | Received |
129-PP-W | Assessments of Pain in US Adults With Hemophilia Across Patient-Reported Outcomes in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study | Jane Cowley | Received |
129-PP-M | Multiple joint procedures (MJP) in haemophilia: benefit of self-reported activities | Piet de Kleijn | Received |
130-PO-T | Robust Fed-Batch Manufacturing Process of Long Acting Factor VIIa (MOD-5014) in CHO Cells | Laura Moschcovich | Received |
130-PP-M | Factors associated with perioperative complications in orthopedic surgery for patients with hemophilia | Jun Hirose | Received |
131-PP-W | Exploring temporal patterns of clotting factor use and associated healthcare utilization in hemophilia | Joanne Wu | Received |
131-PP-M | Assessments of Functional Impairment in US Adults with Hemophilia Across Patient-Reported Outcomes in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study | Jane Cowley | Received |
132-PP-M | Should VTE prophylaxis be applied after total joint replacement in Hemophilia patients? | Anna Seltser | Received |
133-PP-M | Retrospective Study of 14 cases of pseuodotumours in hemophilia From a Comprehensive Haemophilia Care Centre of Western India | chandrakala Shanmukhaiah | Received |
133-PO-T | Clinical and biological characteristics of Haemophilic patients in Ouagadougou (Burkina faso) | Michelle Piot | Received |
133-PO-W | Physical Activity of Severe Haemophilia A Patients Receiving Prophylaxis with Helixate NexGen | Sylvia von Mackensen | Received |
134-PO-T | Global hemostatic assay at different target procoagulant acitivity of factor VIII and factor IX | KIYOUNG YOO | Received |
134-PO-W | Comparing findings on physical examination and ultrasound in adults with haemophilia: a pilot study | Merel Timmer | Received |
135-PO-T | Clinical phenotype of Thai children with hemophilia A | Bunchoo Pongtanakul | Received |
135-PO-W | Daily activities performance of patients with hemophilia in Manado | Stefanus Gunawan Stefanus Gunawan | Received |
135-PP-M | Efficacy and safety of point-of-care ultrasound-guided intra-articular steroid joint injections in patients with hemophilic arthropathy | Emily Martin | Received |
136-PO-W | Assessment of musculoskeletal function & its association with severity of hemophilia | Suresh Hanagavadi | Received |
137-PO-W | Risk management indicators in people with Hemophilia to evaluate results in disease control obtained by health insurers and providers in Colombia | Patricia Sanchez | Received |
137-PP-T | Intra-Articular Injection of Platelet-Rich Plasma versus Hyaluronic Acid Viscosupplementation in Treating Haemophilic Arthropathy of the Knee Joints | Tsung-Ying Li | Received |
138-PP-T | Pain threshold, central sensitization, and relationships with joint dysfunction in haemophilia patients | Carlos Cruz-Montecinos | Received |
138-PO-W | Effect of once-weekly prophylaxis treatment with a recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) on target joints in patients with hemophilia B during the PROLONG-9FP clinical trial program | Carol Hills | Received |
139-PP-T | Patterns of prescription pain medication use among patients with hemophilia (PWH) in the United States based on a commercial insurance claims database | Anshu Shrestha | Received |
139-PO-W | Baseline Characteristics in Hemophilia Utilization Group Studies Part VI (HUGS VI): An Adherence Study among Participants with Hemophilia | Mimi Lou | Received |
139-PO-M | Experience of knee and hip replacement in patients with haemophilia | Tatyana Polyanskaya | Received |
140-PO-M | Total knee arthroplasty when bone ankylosis in a patient suffering from hemophilia A | Vladimir Zorenko | Received |
140-PO-W | LOW DOSES PROPHYLAXIS TREATMENT IN ADULT HEMOPHILIA | EMNA GOUIDER | Received |
140-PO-T | Pain profile in patients with haemophilia | Steffen Krger | Received |
141-PO-M | Does orthopaedic surgery reduce bleeding rate in patients with haemophilia A? | AXON Turoctocog | Received |
141-PO-T | Pain management survey in adult patients with severe hemophilia | Maximiliano Berro | Received |
141-PP-W | Pharmacokinetics of a plasma-derived von VWF/FVIII concentrate (Voncento) in adult/adolescent and pediatric subjects with severe hemophilia A (SWIFT-HA and SWIFTLY-HA studies) | Wilfried Seifert | Received |
142-PP-W | Population pharmacokinetic model of recombinant single-chain factor VIII (rVIII SingleChain) in patients with hemophilia A | Carol Hills | Received |
142-PP-T | Excessive menstrual bleeding in adolescents: study of prevalence and characteristics of defects of hemostasis | Aguirre Rioseco | Received |
143-PO-M | Avascular necrosis of the talus in children with hemophilia: Can it be prevented? Case report and bibliographic revision | Roberto Bernal-Lagunas | Received |
143-PP-T | Home-based factor infusion therapy in hemophilic children | MiKyung Kim | Received |
143-PP-W | Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated adult, adolescent, and paediatric patients with haemophilia B results from two phase 3 trials | Andreas Tiede | Received |
144-PP-T | Central Venous Access Device (CVAD) insertion procedure for pediatric patients with severe hemophilia A: trends in Factor VIII (FVIII) replacement therapy | Valerie Cui | Received |
144-PP-W | Pharmacokinetic (PK)-guided daily dosing: a significant reduction in weekly clotting factor VIII consumption | Iris van Moort | Received |
145-PP-W | Comparison of pharmacokinetic (PK)-guided prophylactic dosing tools in hemophilia A - a pilot study | Tim Preijers | Received |
145-PO-M | Hemophilic Arthropathy: Diagnosis and Treatment of Subchondral Knee Cyst. | Luis Cinara | Received |
146-PP-W | In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients | Tim Preijers | Received |
146-PO-M | Treatment of pseudotumor in patient with hemophilia A and an inhibitor: clinical case. | Vladimir Zorenko | Received |
147-PO-M | MECHANISM OF ACTION OF INTRA-ARTICULAR RIFAMPICINE IN PATIENTS WITH HAEMOPHILIA | María Eulalia Landro | Received |
147-MP-T | The Star Excursion Balance test as a measure of lower limb function in people with Severe Haemophilia. | Fionnuala Sayers | Received |
147-PP-W | The pharmacokinetics characteristics of plasma-derived and recombinant FVIII products in Chinese children with severe hemophilia A. | zhenping chen | Received |
148-PP-W | Pharmacokinetic (PK) profiles in boys with hemophilia A assessed using a population PK Program (myPKFiT) and WinNonlin | Audrey Abad | Received |
148-PP-T | Screening for falls risk in the older person with haemophilia a pilot study of quantitative measures | David Stephensen | Received |
148-PO-M | Hemophilia and reduction of bone mineral density (BMD) | yamina ouarhlent | Received |
149-PO-M | Treatment of adult patients with hemophilic arthropathy, Experience in Mexico | Jonathan Gonzalez | Received |
149-PP-W | Single center clinical and pharmacokinetic experience with long-acting recombinant factor VIII (rFVIIIFx) and IX (rFIXFc) | Devin Malik | Received |
149-PP-T | Swimming exercise prevents bone mass density alteration and modulates bone turnover in an animal model of blood-induced joint damage | Fabio Souza | Received |
150-PP-M | Longitudinal Analysis of Annualized Bleeding Rates Among Adults/Adolescents Receiving Weekly Prophylaxis With rFVIIIFc in A-LONG and ASPIRE | Amy Shapiro | Received |
150-PP-T | When should we interfere to prevent joint damage in Lebanon? | Haddad Cesar | Received |
151-PP-T | Gait analysis by means of accelerometry in patients with haemophilic arthropathy | Sofia Pérez-Alenda | Received |
151-PP-W | Population pharmacokinetic modeling of factor IX activity after administration of nonacog alfa in patients with hemophilia B | Joan Korth-Bradley | Received |
151-PP-M | Evaluation of long-term prophylaxis with a pegylated full-length recombinant factor VIII with extended half-life in patients with hemophilia A | Lisa Patrone | Received |
152-PP-T | Prevalence of gross motor delays in boys with hemophilia ages 4-14: single site study | Grace Hernandez | Received |
152-PP-M | ADHERENCE TO PROPHYLAXIS WITH HELIXATE NEXGEN IN CHILDREN, ADOLESCENT AND ADULT WITH SEVERE HAEMOPHILIA A A PROSPECTIVE OBSERVATIONAL, ITALIAN MULTICENTRE SHAPE STUDY | Sylvia von Mackensen | Received |
153-PP-T | Measuring Achilles Tendon Stiffness in Patients With Haemophilia and Ankle Arthropathy | Carlos Cruz-Montecinos | Received |
153-PP-M | Prophylaxis introduced 13 years ago, retrospective studies, experience in a Brazilian center | JUSSARA ALMEIDA | Received |
153-PO-W | Is weight-based adjustment of factor VIII dosage required for underweight or overweight Japanese patients with hemophilia A? | MEGUMI NOGUCHI | Received |
154-PP-T | Preliminary results in the quantification of physical activity and the relationship with trough levels determined by myPKFiT | Sofia Pérez-Alenda | Received |
155-PP-M | Current status of prophylaxis in haemophilia children ----a multi-center study in China | Ling Tang | Received |
155-PP-T | The role of physical therapy in the WFH Twinning program | Eveline P Mauser-Bunschoten | Received |
156-PO-W | Pharmacokinetics of factor VIII and individualized prophylaxis for severe hemophilia A children in China- a single center data analysis | zhenping chen | Received |
156-PP-M | Successful daily tertiary prophylaxis without increase in factor VIII consumption in a group of severe hemophilia A adolescents | Margareth Ozelo | Received |
156-PP-T | Muscle quality analysis in children with severe and mild haemophilia assessed by ultrasonography | Sofia Pérez-Alenda | Received |
157-PP-T | The effect of hydrotherapy in haemophilic patients after joint replacement in the lower limb | Dčnise Bestetti | Received |
157-PP-W | Phenotypic and Genotypic Characterization of MYH9 related Macrothrombocytopenias in four Portuguese Families | Maria Coutinho | Received |
158-PP-T | Point of care ultrasonography in hemophilia: impact of prior experience and success on competency assessment/evaluation | Karen Strike | Received |
159-PP-W | THE EXPRESSION OF GHRELIN, HSP70, BCL-2 AND BAX PROTEINS IN IDIOPATHIC THROMBOCYTOPENIC PURPURA AT BONE MARROW | Saadet Akarsu | Received |
160-PP-W | Diagnosis of platelet disorders despite normal platelet aggregations | Erika Martin | Received |
160-PP-M | Bioethical analysis of the Brazilian primary prophylaxis protocol | JUSSARA ALMEIDA | Received |
160-PO-T | Joint physical examination (Colorado scale) of osteoporotic hemophilia A patients after resistance training and Pulsed electromagnetic fields | Behrouz Parhampour | Received |
161-PO-T | Severe flexed knee treatment by release of the ipsilateral hip in patients with hemophilia | Carla Daffunchio | Received |
161-PO-M | Tertiary prophylaxis started in adult hemophiliac: experience of a Brazilian Center | Paula Villaca | Received |
162-PO-W | Presence of antiphospholipid antibodies in children with immune thrombocytopenic purpura | Umran Caliskan | Received |
162-PO-M | Single centre experience with the use of Arteriovenous Fistula in children with bleeding disorders | Victoria West | Received |
162-PO-T | FUNCTIONAL OUTCOMES OF TOTAL KNEE ARTHROPLASTY IN PATIENTS WITH HAEMOPHILIA OPERATED WITHOUT TOURNIQUET | Carla Daffunchio | Received |
163-PO-T | Evaluation of Haemophilic arthropathy by thermal images | Sofia Pérez-Alenda | Received |
163-PO-M | Prophylaxis analysis of children hemophilia A in Sichuan Province | Xiaojing LI | Received |
164-PO-T | Conservative management of unyielding knee deformity | Jayashri Kale | Received |
164-PO-M | Identification of the optimal prophylaxis regimen for a physically active child with severe haemophilia A | Rob Herbert | Received |
165-PO-T | The experience of physiotherapy for patients with acquired hemophilia A in a single hemophilia center | Satoko Orita | Received |
165-PO-M | Low-dose short course tertiary prophylaxis in hemophilia A patients with target joint | Bunchoo Pongtanakul | Received |
165-MP-W | Specific therapeutic support and development of the Body Schema in bleeding disorders | NATACHA ROSSO | Received |
166-PO-M | Impact of maintaining higher FVIII trough levels with BAX 855: Rationale and design of the PROPEL study | Andrea Hafeman | Received |
166-MP-W | Psychosocial care for children with congenital bleeding disorders and their parents in the Netherlands | Perrine Limperg | Received |
166-PO-T | Factors influencing knee range of motion after total knee arthroplasty in patients with hemophilia at more than 3 years of follow-up | Minoru Kubota | Received |
167-PO-T | Effectiveness of virtual reality on balance rehabilitation in a patient with hemophilia | Glenda Feldberg | Received |
167-MP-W | Tackling menorrhagia: A potential target to improve psychosocial wellbeing in women with bleeding disorders | Richa Mohan | Received |
168-PO-M | A novel, prospective study reveals the benefit of peak factor VIII protection from the patients perspective | Jason Booth | Received |
169-PO-M | Five years of tailored low dose prophylaxis in a small cohort of kids with severe hemophilia A using SD-F cryoprecipitate | Ahmed Elekiaby | Received |
169-PP-W | The Age of Multicultural Outreach | Elizabeth Fung | Received |
169-PO-T | Haemophilic arthropathy: image evaluation and interobserver reliability | Sofia Pérez-Alenda | Received |
170-PO-M | Annual bleeding rate during prophylaxis: our experience in Argentina | Honnorat, Elhelou, Neme Honnorat | Received |
170-PP-W | Themes in daily life of young adults with congenital bleeding disorders in the Netherlands: a qualitative study | Perrine Limperg | Received |
171-PP-W | Assessments of Anxiety and Depression in US Adult People With Hemophilia Across Patient-Reported Outcomes in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study | Jane Cowley | Received |
171-PO-M | A cohort study of the usefulness of primary prophylaxis in patients with severe hemophilia A in our hospital | Chiai Nagae | Received |
171-PO-T | Physiotherapy of hemophilia in Japan; a survey for physical therapist | Akiko Shimokawa | Received |
172-PP-W | Participation of clinical psychologist in a non-hemophilia treatment center | Jun Yamanouchi | Received |
172-PP-T | Influence of activity on ankle joint presentation | Ann McCarthy | Received |
172-PO-M | LOW DOSES PROPHYLAXIS TREATMENT IN ADULT HEMOPHILIA | kaouther zahra | Received |
173-PP-T | Understanding the Impact of Hemophilia B on Activity of US Children with Hemophilia (CWH) from their Caregivers: The Bridging Hemophilia Experiences Results and Opportunities into Solutions (B-HERO-S Study) | Jane Cowley | Received |
173-PP-W | A bright employment future for persons with bleeding disorders | Brittany Zellner | Received |
174-PO-M | Approaches to optimization of prophylaxis | Rob Herbert | Received |
174-PP-W | Caregiver Burden of Parents of Children with Haemophilia Results from a Single UK Centre | Sylvia von Mackensen | Received |
174-PP-T | Impact of mild to severe hemophilia on engagement in recreational activities by US adult men and women with hemophilia B: the bridging hemophilia B experiences results and opportunities into solutions (B-HERO-S) study | Jane Cowley | Received |
175-PP-W | Case Construction between the psychologist and nurse staff: the experience in a day hospital for hemophiliac patients | Silvia Grases | Received |
175-PP-T | Physical Activity in adult patient with haemophilic arthropathy monitored by Fitbit Charge HR | Sofia Pérez-Alenda | Received |
176-PP-W | Perceived ideal roles of hemophilia treatment center social workers in the United States and barriers to those roles | Margaret Geary | Received |
176-PP-T | New York City Marathon: a challenge for hemophilic patient | Dčnise Bestetti | Received |
177-PO-M | Single centre experience in previouly untreated patients with hemophilia | Basak Koc | Received |
177-PO-T | Applying individualized care to safe physical activity recommendations: an evidence-based resource for persons with bleeding disorders. | Erin McCabe | Received |
178-PP-W | Clinical, Family and Environmental Characterization of in a low income population of person with Hemophilia (PWH) at FUNDOVIDA-Colombia | Antistio Anibal Alviz Amador | Received |
178-PO-T | The Sports effect on the motor development of hemophiliacs | JUSSARA ALMEIDA | Received |
178-MP-M | Comparison of Health Utilities in Persons with Hemophilia B | Joanne Wu | Received |
179-MP-M | Subjective Physical Functioning and Health-Related Quality of Life in Children with Severe Haemophilia in the UK Results of the SO-FIT Study | Sylvia von Mackensen | Received |
179-PP-W | You cannot divorce the Hemophilia | Gaby Golan | Received |
180-PP-W | Life expectancy and lifetime inequalities by settled areas among hemophiliacs with HIV in Japan | Toshiya Kuchii | Received |
180-MP-M | The Patient Reported Outcomes Burdens and Experiences (PROBE) Study Phase 1 Methodology and Feasibility Results | Mark Skinner | Received |
180-PO-T | Pharmacokinetic: APTT; FVIII, FIX level. Is the Prophylaxis effective? | JUSSARA ALMEIDA | Received |
181-PP-M | Health-related quality of life (HRQOL) in young children with haemophilia B treated with the novel long-acting nonacog beta pegol recombinant factor IX | Harley Souter | Received |
181-PP-W | Correlation of pain and life satisfaction among persons with haemophilia | Marko Marinic | Received |
182-PP-W | The Effects of Counseling using NLP( Neuro-Linguistic Programming ) for Improvement in Unsociable Tendency and Interpersonal Anxiety of Hemophilic Arthritis Patients | BAK WON-SOOK | Received |
182-PP-T | Cryopreserved platelets: results from in vitro and in vivo studies | mariasanta napolitano | Received |
182-PP-M | Improvement in health status and quality of life in patients with haemophilia B treated with nonacog beta pegol, an extended half-life glycopegylated recombinant FIX product | Harley Souter | Received |
183-PP-M | Economic Rehabilitation | Nabila Husseni | Received |
184-PP-W | Depression and Anxiety in Adult Haemophilia Patients: Ege Adult Haemophilia Center Experience | Fahri Sahin | Received |
184-PP-T | Shear-dependent interaction of von Willebrand factor with factor VIII and protease ADAMTS13 demonstrated at a single molecule level by atomic force microscopy | Gerald Schrenk | Received |
184-PP-M | Impact of Factor Replacement Therapy on Health-Related Quality of Life: an analysis of pooled data from 254 boys with severe hemophilia | Audrey Abad | Received |
185-PP-W | Psychosocial issues in mothers of children with hemophilia in india | Meera Suresh Hanagavadi | Received |
185-PP-T | Comparison of the pharmacokinetic parameters of a plasma-derived VWF/FVIII concentrate (Voncento) in adult/adolescent and pediatric subjects with von Willebrand disease (SWIFT-VWD and SWIFTLY-VWD study) | Tobias Rogosch | Received |
185-PP-M | Association between Quality of life, Adherence and Satisfaction of Treatment in a low income population of person with Hemophilia (PWH) at FUNDOVIDA- Colombia | ANTISTIO ANIBAL ALVIZ AMADOR | Received |
186-PP-W | Family Meetings in The Hemophilia Society of Turkey | Basak Koc | Received |
186-PP-M | Influence of optimism and resilience on quality of life & general mental health for haemophilia patients | Fiona Brennan | Received |
187-PP-T | Indication for use of VWF containing concentrates in patients with von Willebrand disease | Ana Boban | Received |
187-PP-M | Inhibitor family camp provides a safe haven for children and families to have a camp experience | Eric Lowe | Received |
187-PP-W | Introducing psychodrama as a group psychotherapy with psychosocial benefits in hemophiliacs and their families | Neumann Neumann | Received |
188-PP-M | Beliefs about exercise in persons with severe Haemophilia-a qualitative study. | Steph Taylor | Received |
189-PP-M | Pain, walking, and mobility play essential roles for activities of HIV/HCV-infected people with hemophilia in Japan | Akiko Kakinuma | Received |
189-PP-W | Perception of Self-Esteem of Children with hemophilia from 8 to 12 years according to the degree of arthropathy | Ana Torres-Ortuńo | Received |
190-PP-M | FVII annual retreats help guide patients and families to a better understanding of living with a rare bleeding disorder | Eric Lowe | Received |
190-PO-T | Genotype Characteristics of von Willebrand Disease in Taiwan | Chia-Yau Chang | Received |
190-PP-W | Safe circumcision in haemophilia patients:The Kenyatta National Hospital experience Nairobi Kenya | Anastasia Khasiani | Received |
191-PO-T | Treatment with a Von Willebrand factor concentrate almost devoid of FVIII in patients with von Willebrand disease on antithrombotic therapy | carlos ramirez | Received |
191-PP-M | Healthy living in India... even with hemophilia | NATARAJ SELVARAJ | Received |
192-PP-W | Social work caseloads in hemophilia treatment centers in the United States | Margaret Geary | Received |
192-PO-M | Influence of aging on QOL of HIV-1-infected Japanese hemophiliacs | MIWA OGANE | Received |
193-PO-T | Reliability and validity of the Haemophilia Activities List (HAL) in von Willebrand disease | Karin van Galen | Received |
193-PO-M | CAPACITY BUILDING AND LEADERSHIP INITIATIVE: Bringing change by improving access to care and awareness | Masood Malik | Received |
193-PP-W | The role of the Hemophilia Treatment Center (HTC) Social Worker in the United States | Ellen Kachalsky | Received |
194-PO-M | Summer Camp with Teens | Maria Sol Cruz | Received |
194-PO-T | Reliability and validity of the Haemophilia Joint Health Score (HJHS) in von Willebrand disease | Karin van Galen | Received |
194-PO-W | Psychosocial factors play a role in the adherence of adult patients with hemophilia | Rubén Cuesta-Barriuso | Received |
195-PO-W | NETWORK FOR LIFE | David Andres Cuartas Bolivar | Received |
195-PO-M | Correlation between Hemophilia joint health and Patients Quality of life | Haddad Cesar | Received |
196-PO-W | The impact of parental expectations with a hemophiliac child undergoing treatment | Silvia Grases | Received |
196-PO-M | Change In My Life | Nabila Husseni | Received |
197-PO-T | Orthopedic surgery in a patient affected by von Willebrand disease Type 3: benefits of continuous infusion | Dominique Desprez | Received |
197-PO-W | The psychosocial impact of Hemophilia | Lamia Jouini | Received |
197-PO-M | Evaluation of quality of life in children with hemophilia | Aydogan Gonul | Received |
198-PO-T | Women with von Willebrand disease - a group not mentioned enough | Maneka Ghosh | Received |
198-MP-W | Management of US Boys and Girls with Hemophilia B: Caregiver Insights from the Bridging Hemophilia B Experiences Results and Opportunities into Solutions (B-HERO-S) Study | Jane Cowley | Received |
198-PO-M | Quality of life perceived by pediatric hemophilia patients and their parents in Mexico | Maricela Osorio | Received |
199-PO-T | Clinical Features and Genotypes of 7 Taiwanese Patients with Type 3 von Willebrand Disease | Chia-Yau Chang | Received |
199-MP-M | Pharmacokinetic (PK) Comparison of Two Fibrinogen Concentrates in Patients with Congenital Fibrinogen Deficiency: final analysis. | bruce schwartz | Received |
199-PP-W | Management of US adult men and women patients with hemophilia (PWH): the bridging hemophilia B experiences results and opportunities into solutions (B-HERO-S) study | Jane Cowley | Received |
200-PP-W | Belfast Adults experience of using a pharmacokinetic personalised treatment regime tool to maximise factor replacement | Helen Manson | Received |
200-PO-T | Bleeding score in Type 1 von Willebrand vWD patients using the condensed MCMDM-1 VWD Questionnaire. | ANIL PATHARE | Received |
200-MP-M | Recombinant factor XIII is safe and effective for prophylaxis in young children with congenital FXIII A-subunit deficiency: results from the mentor5 international phase 3 trial | Susan Kearney | Received |
201-PO-T | Screening for von Willebrand disease in women with puberty menorrhagia | Naresh Gupta, M.D. | Received |
201-PP-W | Empowering others to treat; the use of social media for peer support, the benefits, challenges and effectiveness of sharing positive images of intravenous treatment | Cathy Benfield | Received |
201-MP-M | Afibrinogenemia: haemorrhagic and/or thrombotic disease? | Claudia Djambas Khayat | Received |
202-MP-M | Investigation of possible correlation between clinical and laboratory phenotype in congenital FXI deficiency: results from a single center. | Cristina Santoro | Received |
202-PP-W | Home therapy consensus in an under resourced hemophilia setting | Johnny Mahlangu | Received |
203-PP-M | Factor VII deficiency: clinical and genetic features in a cohort from Emilia Romagna Region | Gianna Franca Rivolta | Received |
203-PP-W | Single center, first study in APAC region, on empowering prophylaxis nave families of PWH on self-infusion as home therapy for improved compliance and medical outcomes | chandrakala Shanmukhaiah | Received |
203-PP-T | Kinetics of recombinant Von Willebrand Factor (rVWF) clearance and ADAMTS13-mediated multimer proteolysis in severe Von Willebrand Disease (VWD) | Miranda Chapman | Received |
204-PP-W | Continuous infusion method for life threatening hemorrhage of hemophilia patient | Kun Lee | Received |
204-MP-T | Talking Red. A campaign for women with bleeding disorders | Christina Burgess | Received |
205-MP-T | Gynecologic conditions in post-menarchal adolescents with congenital bleeding disorders (CBD) when compared to adult women a surveillance report of the Female Universal Data Collection project in United States Hemophilia Treatment Center Network | Jane Geyer | Received |
205-PP-M | Molecular basis of factor VII deficiency in a Canadian population study | Julie Gauthier | Received |
206-PP-T | FXI levels and coagulation parameters in women with heavy menstrual bleeding | Sophie Wiewel-Verschueren | Received |
206-PP-M | Phenotype Report on Patients with Congenital Factor V Deficiency in Southern Iran | Mehran Karimi | Received |
206-PO-W | Experience of Self-infusion and Prophylaxis in Pediatric Hemophilia Patients | EM&304;NE TRKKAN | Received |
207-PO-W | Central venous access devices in bleeding disorders in children: experience in Argentina centres. | Monica Martinez | Received |
207-PP-T | Carrier perceptions regarding care and resources elicited from the Carriers: Assessment of REsources (CARE) focus group | Michelle Alabek | Received |
207-PP-M | SPECTRUM OF RARE BLEEDING DISORDERS IN PAKISTAN: CLINICAL PRESENTATION AND PRIMARY CARE | sehar khaliq | Received |
208-PP-T | Reproductive health in females with inherited bleeding disorder | Shabneez Hussain | Received |
209-PP-M | Inhibitor elimination in a high titer haemophilia A patient during long-term prophylaxis with aPCC (FEIBA) | Dr. Carmen Escuriola Ettingshausen | Received |
209-PP-W | Sexual Health in Hemophilia: Identifying and Responding to Healthcare Providers Needs | Lane Shannon | Received |
209-PP-T | A multidisciplinary clinic for women with bleeding disorders: the administration perspective | Antonette Travas | Received |
210-PP-W | Is sexual health education in men with hemophilia needed? The University of California at San Francisco experience | Patricia Tobase | Received |
210-PP-T | A single-centre review of late amniocentesis reliability & satisfaction in carriers of haemophilia | Kayleen Coutts | Received |
211-PP-T | Building Each Other, One Country At A Time | Andrea Trinidad Echavez | Received |
211-PP-W | Activities and participation in sexuality and bleeding disorders | Eveline Mauser-Bunschoten | Received |
212-PO-M | The treatment and prophylaxis with cryoprecipitate of spontaneous intracranial bleeding in a patient with mild inherited factor XIII deficiency | Ebru Yilmaz | Received |
212-PO-T | Association of factor V Leiden G1691A and prothrombin gene G20210A mutation with adverse pregnancy outcomes | Sidra Asad Ali | Received |
213-PO-T | The Lioness and the young Lion A case report | Gina Goldstein | Received |
214-PO-M | Assessment of ed ROTEM parameters, kinetics of fibrinogen polymerization and plasmin amidolytic activity in patients with congenital fibrinogen defects | Jacek Trelinski | Received |
24-28 July 2016 Orlando
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. |
||||